Integra LifeSciences (NASDAQ:IART – Get Free Report) released its quarterly earnings data on Monday. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. The company had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.71 earnings per share.
Integra LifeSciences Trading Down 1.1 %
Shares of Integra LifeSciences stock traded down $0.29 on Tuesday, hitting $25.13. 791,537 shares of the company’s stock traded hands, compared to its average volume of 1,121,136. Integra LifeSciences has a one year low of $22.36 and a one year high of $46.09. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The stock has a market capitalization of $1.98 billion, a PE ratio of 50.84, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11. The firm’s 50-day moving average price is $29.72 and its two-hundred day moving average price is $33.65.
Insider Buying and Selling
In related news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the purchase, the chairman now owns 487,922 shares of the company’s stock, valued at approximately $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 3.10% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Integra LifeSciences
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- Pros And Cons Of Monthly Dividend Stocks
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
- What Are Growth Stocks and Investing in Them
- This Semiconductor Stock Is ON Track for a New High
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.